Taysha Gene Therapies (TSHA) Stock News
$TSHA · NASDAQ · 1 stories in 30 daysBORSA has published 1 story on Taysha Gene Therapies (TSHA) in the past 30 days, 1 of it high impact. BORSA’s news read on TSHA is bullish at 76/100, based on 1 company event over the past 7 days. TSHA last closed at $4.21 on Nov 12, up 2.93% over five sessions and up 19.94% over the past month.
The wire on $TSHA
newest first · updated · direct subject stories onlyTaysha Gene Therapies posted a Q3 net loss of $39.1M, or $0.10 per share, with no revenue. Cash runway extends into 2H 2028. TSHA-102 safety profile remains clean; manufacturing PPQ completed. Key FDA interactions and interim data expected in 1H 2027.
bullish 80 · impact 70The wire on this name is open. What the tape did about it is one free account away.
One free account opens every story complete, the live board and the 30-day calendar, and 3 complete ticker and report views a day. No card. The wire stays free to read.
Taysha Gene Therapies (TSHA) stock: common questions
What is the latest Taysha Gene Therapies stock news?
The highest-impact TSHA story BORSA published in the past 30 days:
· Taysha Gene Therapies reports Q3 net loss of $39.1M, advances TSHA-102 toward potential BLA submission